259 related articles for article (PubMed ID: 19147181)
1. Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review.
Massara A; Cavazzini L; La Corte R; Trotta F
Semin Arthritis Rheum; 2010 Feb; 39(4):313-9. PubMed ID: 19147181
[TBL] [Abstract][Full Text] [Related]
2. [Sarcoïdosis and anti-TNF: a paradoxical class effect? Analysis of the French Pharmacovigilance system database and literature review].
Javot L; Tala S; Scala-Bertola J; Massy N; Trenque T; Baldin B; Andréjak M; Gillet P; Petitpain N;
Therapie; 2011; 66(2):149-54. PubMed ID: 21635863
[TBL] [Abstract][Full Text] [Related]
3. Sarcoidosis-like granulomatosis of the hypopharynx as a complication of anti-TNF therapy.
Christoforidou A; Goudakos J; Bobos M; Lefkaditis E; Vital V; Markou K
Am J Otolaryngol; 2013; 34(3):268-72. PubMed ID: 23357593
[TBL] [Abstract][Full Text] [Related]
4. [Lupus like syndrome induced by treatment with anti TNFalpha (infliximab): report of three cases].
Benucci M; Nenci G; Cappelletti C; Manfredi M
Recenti Prog Med; 2008; 99(7-8):363-6. PubMed ID: 18751615
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series.
Toussirot E; Berthelot JM; Pertuiset E; Bouvard B; Gaudin P; Wendling D; le Noach J; Lohse A; Lecuyer E; Cri L
J Rheumatol; 2009 Nov; 36(11):2421-7. PubMed ID: 19797509
[TBL] [Abstract][Full Text] [Related]
6. Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases.
Toussirot E; Pertuiset E; Kantelip B; Wendling D
Clin Exp Rheumatol; 2008; 26(3):471-5. PubMed ID: 18578973
[TBL] [Abstract][Full Text] [Related]
7. Sarcoid-related uveitis occurring during adalimumab therapy.
Seve P; Varron L; Broussolle C; Denis P; Kodjikian L
Ocul Immunol Inflamm; 2012 Feb; 20(1):59-60. PubMed ID: 22017197
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor-alpha antagonist-induced sarcoidosis.
Clementine RR; Lyman J; Zakem J; Mallepalli J; Lindsey S; Quinet R
J Clin Rheumatol; 2010 Sep; 16(6):274-9. PubMed ID: 20808167
[TBL] [Abstract][Full Text] [Related]
9. Sarcoid intermediate uveitis following etanercept treatment: a case report and review of the literature.
Fonollosa A; Artaraz J; Les I; Martinez-Berriotxoa A; Izquierdo JP; Lopez AS; Gardeazaba J; Berasategui B; Martinez-Alday N
Ocul Immunol Inflamm; 2012 Feb; 20(1):44-8. PubMed ID: 22017171
[TBL] [Abstract][Full Text] [Related]
10. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis.
Stokes MB; Foster K; Markowitz GS; Ebrahimi F; Hines W; Kaufman D; Moore B; Wolde D; D'Agati VD
Nephrol Dial Transplant; 2005 Jul; 20(7):1400-6. PubMed ID: 15840673
[TBL] [Abstract][Full Text] [Related]
11. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
12. Sarcoidosis during infliximab therapy for Crohn's disease.
Takahashi H; Kaneta K; Honma M; Ishida-Yamamoto A; Ashida T; Kohgo Y; Ohsaki Y; Iizuka H
J Dermatol; 2010 May; 37(5):471-4. PubMed ID: 20536653
[TBL] [Abstract][Full Text] [Related]
13. Sarcoidosis triggered by interferon-Beta treatment of multiple sclerosis: a case report and focused literature review.
Chakravarty SD; Harris ME; Schreiner AM; Crow MK
Semin Arthritis Rheum; 2012 Oct; 42(2):206-12. PubMed ID: 22572392
[TBL] [Abstract][Full Text] [Related]
14. [Sarcoidosis after adalimumab treatment in inflammatory rheumatic diseases: a report of two cases and literature review].
Scailteux LM; Guedes C; Polard E; Perdriger A
Presse Med; 2015 Jan; 44(1):4-10. PubMed ID: 25534463
[TBL] [Abstract][Full Text] [Related]
15. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.
Lee JH; Slifman NR; Gershon SK; Edwards ET; Schwieterman WD; Siegel JN; Wise RP; Brown SL; Udall JN; Braun MM
Arthritis Rheum; 2002 Oct; 46(10):2565-70. PubMed ID: 12384912
[TBL] [Abstract][Full Text] [Related]
16. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.
Deng A; Harvey V; Sina B; Strobel D; Badros A; Junkins-Hopkins JM; Samuels A; Oghilikhan M; Gaspari A
Arch Dermatol; 2006 Feb; 142(2):198-202. PubMed ID: 16490847
[TBL] [Abstract][Full Text] [Related]
17. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
18. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.
Girolomoni G; Altomare G; Ayala F; Berardesca E; Calzavara-Pinton P; Chimenti S; Peserico A; Puglisi Guerra A; Vena GA
Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):548-60. PubMed ID: 22296031
[TBL] [Abstract][Full Text] [Related]
19. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
20. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.
Slifman NR; Gershon SK; Lee JH; Edwards ET; Braun MM
Arthritis Rheum; 2003 Feb; 48(2):319-24. PubMed ID: 12571839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
